FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293776329> ?p ?o ?g. }

• W4293776329 endingPage "224" @default.
• W4293776329 startingPage "224" @default.
• W4293776329 abstract "Background and Aims : The main purpose of the study is to evaluate the effectivity, safety and adherence in patients who undergoing treatment with PSCK9 inhibitors (iPCKS9), evolocumab and alirocumab, in our Lipid Unit of ALTHAIA. Xarxa assistencial universitarà de Manresa (Barcelona).Methods: Prospective observational follow-up study since may 2016 until june 2021. Patients were on standard of care and didn't achieve cLDL goals, furthermore they met the local criteria (CAMHDA) to start treatment with iPCSK9. We took blood samples to assess lipid profile at 1,3,6 months and then every 6 months. We evaluated cLDL targets according to ESC/EAS 2019 Guidelines for the management of dyslipidaemias.Results: N= 43. Women 17/43 (39,53%). 19/43 (44%) presented Heterozygous Familiar Hypercolesterolemia (FH). They were on secondary prevention 31/43 (72,09%), 10/31 (32%) of them with FH. 19/43 (44%) presented total intolerance to statins. Efectivity Patients presented a reduction of cLDL from baseline of 54,75% to 69,85%. Most of them (>63%) achieved cLDL goals time-maintained. We only observed 4 cases who presented a one-off increase. We observed 4 cases of MACE: 2/4 at the begining of iPCKS9 therapy, 1/4 in a patient who was active smoker and had poor drug adherence, and 1/4 in uncontrolled diabetis with cLDL <55mg/dl. Safety Evolocumab: 1/43 diarrhea, 1/43 flu syndrome Alirocumab: 1/43 myalgia, 1/43 severe skin reaction Adherence Patients presented an adherence >95% and felt comfortable with their administration regimen.Conclusions: Most of patients who undergoing treatment with PCSK9 inhibitors achieve cLDL goals, present low rates of adverse effects and have a good adherence. Background and Aims : The main purpose of the study is to evaluate the effectivity, safety and adherence in patients who undergoing treatment with PSCK9 inhibitors (iPCKS9), evolocumab and alirocumab, in our Lipid Unit of ALTHAIA. Xarxa assistencial universitarà de Manresa (Barcelona). Methods: Prospective observational follow-up study since may 2016 until june 2021. Patients were on standard of care and didn't achieve cLDL goals, furthermore they met the local criteria (CAMHDA) to start treatment with iPCSK9. We took blood samples to assess lipid profile at 1,3,6 months and then every 6 months. We evaluated cLDL targets according to ESC/EAS 2019 Guidelines for the management of dyslipidaemias. Results: N= 43. Women 17/43 (39,53%). 19/43 (44%) presented Heterozygous Familiar Hypercolesterolemia (FH). They were on secondary prevention 31/43 (72,09%), 10/31 (32%) of them with FH. 19/43 (44%) presented total intolerance to statins. Efectivity Patients presented a reduction of cLDL from baseline of 54,75% to 69,85%. Most of them (>63%) achieved cLDL goals time-maintained. We only observed 4 cases who presented a one-off increase. We observed 4 cases of MACE: 2/4 at the begining of iPCKS9 therapy, 1/4 in a patient who was active smoker and had poor drug adherence, and 1/4 in uncontrolled diabetis with cLDL <55mg/dl. Safety Evolocumab: 1/43 diarrhea, 1/43 flu syndrome Alirocumab: 1/43 myalgia, 1/43 severe skin reaction Adherence Patients presented an adherence >95% and felt comfortable with their administration regimen. Conclusions: Most of patients who undergoing treatment with PCSK9 inhibitors achieve cLDL goals, present low rates of adverse effects and have a good adherence." @default.
• W4293776329 created "2022-08-31" @default.
• W4293776329 creator A5007257797 @default.
• W4293776329 creator A5022033022 @default.
• W4293776329 creator A5060612742 @default.
• W4293776329 creator A5065768156 @default.
• W4293776329 creator A5081265035 @default.
• W4293776329 creator A5083678766 @default.
• W4293776329 date "2022-08-01" @default.
• W4293776329 modified "2023-09-28" @default.
• W4293776329 title "Effectivity, safety and adherence with PCKS9 inhibitors" @default.
• W4293776329 doi "https://doi.org/10.1016/j.atherosclerosis.2022.06.876" @default.
• W4293776329 hasPublicationYear "2022" @default.
• W4293776329 type Work @default.
• W4293776329 citedByCount "0" @default.
• W4293776329 crossrefType "journal-article" @default.
• W4293776329 hasAuthorship W4293776329A5007257797 @default.
• W4293776329 hasAuthorship W4293776329A5022033022 @default.
• W4293776329 hasAuthorship W4293776329A5060612742 @default.
• W4293776329 hasAuthorship W4293776329A5065768156 @default.
• W4293776329 hasAuthorship W4293776329A5081265035 @default.
• W4293776329 hasAuthorship W4293776329A5083678766 @default.
• W4293776329 hasBestOaLocation W42937763291 @default.
• W4293776329 hasConcept C126322002 @default.
• W4293776329 hasConcept C1862650 @default.
• W4293776329 hasConcept C23131810 @default.
• W4293776329 hasConcept C2778114629 @default.
• W4293776329 hasConcept C2778163477 @default.
• W4293776329 hasConcept C2778616394 @default.
• W4293776329 hasConcept C2780745583 @default.
• W4293776329 hasConcept C2780902209 @default.
• W4293776329 hasConcept C2781413609 @default.
• W4293776329 hasConcept C62746215 @default.
• W4293776329 hasConcept C71924100 @default.
• W4293776329 hasConceptScore W4293776329C126322002 @default.
• W4293776329 hasConceptScore W4293776329C1862650 @default.
• W4293776329 hasConceptScore W4293776329C23131810 @default.
• W4293776329 hasConceptScore W4293776329C2778114629 @default.
• W4293776329 hasConceptScore W4293776329C2778163477 @default.
• W4293776329 hasConceptScore W4293776329C2778616394 @default.
• W4293776329 hasConceptScore W4293776329C2780745583 @default.
• W4293776329 hasConceptScore W4293776329C2780902209 @default.
• W4293776329 hasConceptScore W4293776329C2781413609 @default.
• W4293776329 hasConceptScore W4293776329C62746215 @default.
• W4293776329 hasConceptScore W4293776329C71924100 @default.
• W4293776329 hasLocation W42937763291 @default.
• W4293776329 hasOpenAccess W4293776329 @default.
• W4293776329 hasPrimaryLocation W42937763291 @default.
• W4293776329 hasRelatedWork W1530703804 @default.
• W4293776329 hasRelatedWork W2030548521 @default.
• W4293776329 hasRelatedWork W2288476146 @default.
• W4293776329 hasRelatedWork W2810622115 @default.
• W4293776329 hasRelatedWork W2884577329 @default.
• W4293776329 hasRelatedWork W3163316465 @default.
• W4293776329 hasRelatedWork W3201560478 @default.
• W4293776329 hasRelatedWork W4226289380 @default.
• W4293776329 hasRelatedWork W4293579115 @default.
• W4293776329 hasRelatedWork W4310457218 @default.
• W4293776329 hasVolume "355" @default.
• W4293776329 isParatext "false" @default.
• W4293776329 isRetracted "false" @default.
• W4293776329 workType "article" @default.